Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease

  1. Socinski, M.A.
  2. Kaye, F.J.
  3. Spigel, D.R.
  4. Kudrik, F.J.
  5. Ponce, S.
  6. Ellis, P.M.
  7. Majem, M.
  8. Lorigan, P.
  9. Gandhi, L.
  10. Gutierrez, M.E.
  11. Nepert, D.
  12. Corral, J.
  13. Ares, L.P.
Revue:
Clinical Lung Cancer

ISSN: 1938-0690,  1525-7304

Année de publication: 2017

Volumen: 18

Número: 1

Pages: 68-76.e2

Type: Article

DOI: 10.1016/J.CLLC.2016.09.002 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus